View Older Stories

Jan 9, 2026 05:51AM BTIG Upgrades Moonlake Immunotherapeutics (MLTX) to Buy

Jan 8, 2026 08:51AM Moonlake Immunotherapeutics (MLTX) PT Raised to $45 at Clear Street

Jan 8, 2026 08:05AM MoonLake receives FDA guidance for drug approval without new trials

Nov 21, 2025 06:40AM Moonlake Immunotherapeutics (MLTX) PT Lowered to $26 at H.C. Wainwright

Nov 5, 2025 07:11AM MoonLake prices $75 million stock offering at $10.50 per share

Nov 3, 2025 06:38AM H.C. Wainwright Upgrades Moonlake Immunotherapeutics (MLTX) to Buy

Oct 7, 2025 09:04AM Moonlake Immunotherapeutics (MLTX) PT Lowered to $25 at Oppenheimer

Oct 3, 2025 09:56AM Increasing unusual call option volume: MLTX RVPH OVID KDK LAC PLUG CAN TD GSRT FINV

Oct 2, 2025 06:42AM H.C. Wainwright Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral

Sep 30, 2025 04:27PM Goldman Sachs Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral

Sep 30, 2025 07:11AM Moonlake Immunotherapeutics (MLTX) PT Lowered to $20 at Needham

Sep 30, 2025 06:42AM Moonlake Immunotherapeutics (MLTX) PT Lowered to $20 at Guggenheim, removed as Best Idea

Sep 29, 2025 04:38PM Moonlake Immunotherapeutics (MLTX) PT Lowered to $12 at Clear Street

Sep 29, 2025 02:51PM MoonLake Immunotherapeutics (MLTX) call put ratio 3.9 calls to 1 put with a focus on October 80 calls as share price down 90%

Sep 29, 2025 01:57PM Jefferies Downgrades Moonlake Immunotherapeutics (MLTX) to Hold, 'Growing Uncertainty in SLK Path Fwd and Dimmed Commercial Outlook'

Sep 29, 2025 06:56AM Wedbush Reiterates Outperform Rating on Moonlake Immunotherapeutics (MLTX)

Sep 29, 2025 06:41AM BTIG Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral

Sep 29, 2025 01:10AM Stifel Downgrades Moonlake Immunotherapeutics (MLTX) to Hold

Sep 29, 2025 12:49AM RBC Capital Downgrades Moonlake Immunotherapeutics (MLTX) to Sector Perform

Sep 22, 2025 06:12AM Increasing unusual put option volume: INFY BHF SNDK CRON PTLO CBRL BITF K DXCM XRX MLTX

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Aug 5, 2025 12:26PM Guggenheim on 'Best Idea' Moonlake Immunotherapeutics (MLTX): 'We Continue To Anticipate Highly Positive Pivotal HS Readout Around Sept (2H)'

Aug 5, 2025 07:49AM MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c

Aug 5, 2025 05:40AM Clear Street Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Jul 28, 2025 05:48AM Rothschild & Co Redburn Starts Moonlake Immunotherapeutics (MLTX) at Neutral

Jun 5, 2025 03:35PM MoonLake Immunotherapeutics (MLTX) call put ratio 1 call to 9 puts as share price down 4.7%

Jun 5, 2025 05:58AM MoonLake Immunotherapeutics (MLTX) call put ratio 1 call to 2.5 puts amid recent rally

Jun 3, 2025 09:31AM RBC Capital: 'Moonlake Immunotherapeutics (MLTX) Remains A Top Catalyst-Driven Idea'

Jun 3, 2025 05:52AM Guggenheim: Moonlake Immunotherapeutics (MLTX) remains our Best Idea

Jun 2, 2025 04:52PM Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT

May 27, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

May 19, 2025 10:30AM Wolfe Research Upgrades Moonlake Immunotherapeutics (MLTX) to Outperform

May 13, 2025 06:47AM MoonLake Immunotherapeutics (MLTX) Tops Q1 EPS by 13c

Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets

Apr 4, 2025 07:16AM Cantor Fitzgerald Reiterates Overweight Rating on Moonlake Immunotherapeutics (MLTX)

Mar 19, 2025 04:54AM BTIG Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Mar 17, 2025 01:48PM Guggenheim Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX), Top Pick

Mar 12, 2025 11:30AM TD Cowen: 'Moonlake Immunotherapeutics (MLTX) is a Europe Best Idea'

Dec 12, 2024 01:18PM Clear Street Starts Moonlake Immunotherapeutics (MLTX) at Buy

Oct 15, 2024 06:32AM H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Sep 12, 2024 08:55AM TD Cowen Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Sep 12, 2024 07:47AM H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Sep 12, 2024 05:16AM BTIG Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Aug 26, 2024 06:03AM Wolfe Research Downgrades Moonlake Immunotherapeutics (MLTX) to Peerperform

Jul 1, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

Jun 24, 2024 04:10PM Oppenheimer Starts Moonlake Immunotherapeutics (MLTX) at Outperform

Jun 10, 2024 07:02AM MoonLake Immunotherapeutics (MLTX) Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis

View Older Stories